APYX Q1 2026: Revenue Up, Loss Narrowed, International Push Signals Growth for Sector Peers
In its first quarter of 2026, APYX — the NASDAQ-listed operator behind Renuvion and the AYON Body Contouring System — posted total revenue of $12.5 million for the quarter ended March 31, 2026, driven almost entirely by a Surgical Aesthetics segment that delivered $10.7 million. The remaining revenue came from OEM sales of approximately $1.8 million. The company also reported a net loss of $2.1 million and an Adjusted EBITDA loss of $0.3 million, continuing a pattern of near-term profitability pressure, but with improving trends versus year-ago results.
Importantly for investors, management raised the 2026 revenue forecast to a range of $59.0 million to $60.0 million. There is no per-share (EPS) data in the release, so the current quarter’s results do not include an EPS figure or an immediate EPS consensus versus expectation. Still, the direction of travel is clear: stronger top-line growth is lapping into a tighter loss profile, even as the company remains unprofitable on a GAAP basis for now.
Revenue mix keeps marching forward
The quarter highlights a simple arithmetic story: Surgical Aesthetics revenue of $10.7 million carried the day, up from $7.9 million in the first quarter of 2025. OEM revenue rose about 13.8% year over year to roughly $1.8 million. With total revenue landing at $12.5 million, the mix confirms that the core growth engine remains the flagship aesthetic portfolio rather than ancillary lines.
Management framed the results within a regional context: international sales exceeded expectations, aided in part by regulatory clearance in December 2025 and ongoing adoption of the Apyx One Console and single-use handpieces in growth markets like South Korea. This dynamic suggests that the company’s international footprint may become more material as regulatory paths converge with demand in Asia Pacific markets.
International momentum and product cadence
A notable driver of the quarter was international demand, including early traction in South Korea after regulatory approval late in 2025. The South Korea market has been described as a sizable growth opportunity, with cosmetic surgery activity estimated at $1.7 billion in 2024 and projected to exceed $3.9 billion by 2031. The company highlighted sales of the Apyx One Console and single-use handpieces as contributing factors to the upside, underscoring the potential for international expansion to support higher revenue in upcoming quarters.
Profitability bar: closer but not yet clear
On a GAAP basis, net loss narrowed to $2.1 million in Q1 2026 from a $4.2 million loss in Q1 2025. The Adjusted EBITDA loss narrowed to $0.3 million from $2.4 million in the prior-year period. These metrics suggest cost discipline and operational leverage are improving, even as the company remains cash-losing at the operating level. For investors focused on EPS and corresponding earnings surprises, the trajectory will hinge on sustaining top-line strength alongside continued progress toward breakeven or positive EBITDA in the coming quarters.
Guidance, expectations, and sector read-through
The raised revenue forecast for 2026 reflects management’s confidence in continued demand for Surgical Aesthetics offerings and the international expansion plan. While the press release does not provide a formal EPS consensus figure or a disclosed EPS target for 2026, the shift in revenue guidance implies that the market may soon be focusing more on per-share metrics as the company approaches a potential inflection point. Investors will want to see how the revenue mix, margin progression, and international regulatory progress translate into a more favorable earnings per share trajectory.
For sector peers in medical devices and aesthetic technologies, APYX’s Q1 2026 narrative underscores a broader theme: growth in high-value, clinician-adjacent devices can be accelerated by regulatory approvals in key Asian markets and the ongoing monetization of recurring consumables (like single-use handpieces). The durability of this model depends on how well players translate top-line expansion into unit economics and what the next rounds of regulatory milestones portend for market access.
Bottom line: progress with caveats
APYX’s first quarter shows a disciplined path: revenue lift in the core Surgical Aesthetics segment, a meaningful international uptick, and a narrowing but still negative bottom-line picture. The updated revenue forecast sets a clear target for 2026, and investors will scrutinize EPS trajectories and any acceleration in gross margins as a signal that the company can convert growth into sustainable profitability. The sector will watch whether Asia-Pacific momentum and the recurring nature of consumables can deliver a durable earnings surprise for APYX and its peers in the near horizon.